{"id":"W2769972801","doi":"10.1158/1078-0432.ccr-17-1590","title":"A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors","year":2017,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université Laval","funders":"National Cancer Institute; Ovarian Cancer Research Fund","keywords":"Veliparib; Topotecan; Medicine; PARP inhibitor; Internal medicine; Neutropenia; Olaparib; Oncology; Febrile neutropenia; Gastroenterology; Clinical endpoint; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Surgery; Pharmacology; Clinical trial; Chemotherapy; Poly ADP ribose polymerase; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.004834375,0.0002127029,0.0009469802,0.0001574499,0.0003759486,0.0000741093,0.000583373,0.0002925,0.0001905359],"category_scores_gemma":[0.003332727,0.000140366,0.0002328415,0.0002965267,0.003175614,0.0001537446,0.0003760136,0.001901856,0.000009251147],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000177166,"about_ca_system_score_gemma":0.00173505,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009708455,"about_ca_topic_score_gemma":0.000324133,"domain_scores_codex":[0.9948389,0.0009285781,0.001557159,0.0007284014,0.001323645,0.0006233032],"domain_scores_gemma":[0.9958495,0.001004498,0.0005649136,0.001553397,0.000536579,0.0004911117],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.2412556,0.006320131,0.6428423,0.00009291596,0.000147994,0.00003663909,0.0001566869,3.792281e-7,0.000196075,0.00006147293,0.004602334,0.1042875],"study_design_scores_gemma":[0.3565684,0.0161911,0.6173348,0.001136906,0.00006131913,0.000002573534,0.00007486863,0.00004276927,0.003285452,0.0002112758,0.00485351,0.0002370375],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9855728,0.0003563994,0.000004126634,0.01040831,0.001037927,0.001916827,0.0001063468,0.00001580826,0.0005815134],"genre_scores_gemma":[0.996033,0.0003504369,0.00005647352,0.0005833582,0.002227594,0.0002021178,0.000007921826,0.0000433375,0.0004957694],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1153129,"threshold_uncertainty_score":0.9995372,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2537814787584608,"score_gpt":0.5781930088015869,"score_spread":0.3244115300431261,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}